CancerLinQ is a health technology company focused on improving cancer care quality and clinical research with real-world data and advanced analytics.
Cambridge, MA
Joined April 2021
- Tweets611
- Following192
- Followers1.4K
- Likes288
CancerLinQ® retweeted
Thanks @Politico for robust discussion on #CancerMoonshot today w/our CEO Dr. @CliffordHudis, who shared: “Making really great scientific advances & failing to get them to every patient who could benefit is an avoidable failure on our part." #ASCOAdvocacy
CancerLinQ® retweeted
Discover how data-driven approaches to #covariateadjustment help de-risk and accelerate #clinicaltrials in @BioCentury's latest report.
go.biocentury.com/WB-2022-06…
Watch the on-demand webinar landingpage.owkin.com/covari…
CancerLinQ® retweeted
The CancerLinQ-Atropos collaboration is part of a new portfolio of partnerships designed to deliver innovative solutions to CancerLinQ’s oncology practices, patients, and the cancer research community we serve: cancerlinq.org/about/collabo…
CancerLinQ® retweeted
Interested in learning more about how real-world evidence can advance precision medicine in radiation oncology? If you’re at @CI4CC, tune into Atropos Health’s keynote speech - Real World Evidence at the LINAC - at 11:15AM PT today. @whysquaredmdphd #datascience #informatics
CancerLinQ® retweeted
#AI algorithms trained on #EHR data will undoubtedly play an increasingly important role in supporting clinical decisions. At @ASCOCancerLinQ, we’re working with @AtroposHealth to deploy #ML derived models to help oncologists personalize treatments atroposhealth.com/asco-cance…
CancerLinQ® retweeted
Machine Learning Models Predict Liver Cancer Treatment Response healthitanalytics.com/news/m…
CancerLinQ® retweeted
ICYMI: Check out the latest @ASCOCancerLinQ podcast on a recently published paper in @JCOOP_ASCO: Incidence of SARS-CoV-2 and Subsequent Mortality in a Multisite Cohort of Patients with Cancer in the #CancerLinQ Discovery Database 👇 #covid19ncancer
First author Dr. Emily Ray from UNC speaks to CancerLinQ Chief Medical Science Officer to discuss these findings in the latest edition of the CancerLinQ Video Podcast youtube.com/watch?v=muOW4hPK… 3/3
CancerLinQ® retweeted
In @ASCO's latest post, @TClozel, our Co-founder and CEO, and @SeanKhozin, CEO of @ASCOCancerLinQ and EVP of the @ASCO, discuss how the partnership will help break through silos and advance #medical research to improve #lungcancer treatment for patients.
CancerLinQ® retweeted
A call to action by one of the greatest minds of our time. Prof Lo of @MIT on responsible use of financial engineering, venture philanthropy, & impact investing to advance breakthroughs in oncology.
Innovative science needs innovative finance to thrive.
forbes.com/sites/russellflan…
CancerLinQ® retweeted
Incoming @theNCI director @bertagnollimm's background also includes being the founding chair of mCODE, an open standard for oncology data & @SeanKhozin (ex FDA Oncology) said she catalyzed effort poised to reshape landscape of learning system in oncology linkedin.com/feed/update/urn…
CancerLinQ® retweeted
EHR data's not just messy; it's transactional and decontextualized. That's why we are creating CancerLinQ Patient Intelligence 360, to place raw EHR data into familiar disease phases and treatment settings recognizable to clinicians
In our latest blog post, Jose Mena, Director of Data and Bioinformatics, talks about why he's excited about CancerLinQ Patient Intelligence 360. Read it here ➡️ fal.cn/3qNWs
CancerLinQ® retweeted
Looking forward to having Dr. Dizon share his insights with the CancerLinQ network and broader community. Sign-up link below
We're excited to announce that @drdonsdizon, will be leading our next speaker series event, on 9/14 at 1pm ET, to discuss disparities across the cancer continuum. Registration starts today! fal.cn/3qL7I
CancerLinQ® retweeted
#Inception Premier member @OWKINscience is collaborating with @ASCOCancerLinQ to use #federatedlearning on real-world oncology data. Their goal is to better understand the treatment of lung cancer to improve patient outcomes.
Learn more > nvda.ws/3Ba9JNm
CancerLinQ® retweeted
Dr. @bertagnollimm is exactly the person the country (and the world) needs to lead @theNCI. She can move mountains with agility, grace, and precision.
The Biden administration has selected Monica Bertagnolli, a renowned surgical oncologist, as the next director of the National Cancer Institute, according to two sources familiar with the decision. buff.ly/3z0jbAe
CancerLinQ® retweeted
Congratulations @bertagnollimm! One of the smartest and most passionate oncology clinicians, researchers, and leaders working in our field today. It has been a pleasure collaborating with you on #CancerLinQ and #mCODE. Looking forward to your innovative leadership of #NCI
This Post is from an account that no longer exists. Learn more
CancerLinQ® retweeted
We are delighted to announce a partnership with @ASCO's @ASCOCancerLinQ to use federated learning on real-world oncology data from the US and Europe to better understand lung cancer treatment.
Learn more at asco.org/about-asco/press-ce…
CancerLinQ® retweeted
We're very excited at #CancerLinQ to be partnering w/ @OwkinScience, a leader in federated learning, on this initial project! Looking forward to many fruitful future collaborations on other scientific projects answering important clinical questions, enabled by this technology
We're excited to announce a new collaboration with @OwkinScience to use artificial intelligence to analyze real-world oncology data with the aim to better understand metastatic non-small cell lung cancer and first-line immunotherapy treatment. fal.cn/3q2TM
CancerLinQ® retweeted
AAIH Member Spotlight: Congratulations to #AAIH members @ASCOCancerLinQ and @OwkinScience on their collaboration! 🎉
We're excited to announce a new collaboration with @OwkinScience to use artificial intelligence to analyze real-world oncology data with the aim to better understand metastatic non-small cell lung cancer and first-line immunotherapy treatment. fal.cn/3q2TM
CancerLinQ® retweeted
ASCO's @ASCOCancerLinQ announced new research collab w/Paris-based @OwkinScience to use AI to analyze real-world oncology data to study why some cases of metastatic non-small cell lung cancer (NSCLC) are resistant to first-line immunotherapy 1/n treatment.asco.org/about-asco/press-ce…